博瑞医药：噻托溴铵吸入粉雾剂获药物临床试验批准

Core Viewpoint - The announcement indicates that the subsidiary Aitemei (Suzhou) Pharmaceutical Technology Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of Tiotropium Bromide Inhalation Powder for the treatment of Chronic Obstructive Pulmonary Disease (COPD) [1] Group 1 - Aitemei has been granted a Clinical Trial Approval Notice for Tiotropium Bromide Inhalation Powder, which is intended for use in COPD [1] - The projected domestic sales for Tiotropium Bromide Inhalation Powder are 555 million yuan in 2022, 522 million yuan in 2023, and 493 million yuan in 2024 [1] - The drug must undergo clinical trials and receive further approval before it can be manufactured and marketed, indicating that there will be no significant short-term impact on the company's operations [1]